Randomized Trial of Suicide Gene Therapy and Prostate Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, controlled trial that will test the hypothesis that replication-competent adenovirus-mediated suicide gene therapy in combination with 80 Gy intensity modulated radiotherapy (IRMT)will improve freedom from failure (FFF) relative to 80 Gy IMRT alone in patients with newly-diagnosed prostate cancer with an intermediate-risk profile.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer

NCT02555397

Prostate Cancer

COMPLETED PHASE1

T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy

NCT05361798

Cancer Of Prostate

RECRUITING PHASE2

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

NCT00528866

Prostate Cancer

COMPLETED PHASE2

Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate

NCT01255891

Adenocarcinoma of the Prostate

COMPLETED PHASE2

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

NCT00589472

Prostate Adenocarcinoma Stage I Prostate Cancer Stage IIA Prostate Cancer +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES

This is a randomized, controlled trial that will test the hypothesis that replication-competent adenovirus-mediated suicide gene therapy in combination with 80 Gy intensity modulated radiotherapy (IRMT)will improve freedom from failure (FFF) relative to 80 Gy IMRT alone in patients with newly-diagnosed prostate cancer with an intermediate-risk profile.

The trial contains two treatment arms:

Arm 1- Gene Therapy + IMRT Arm 2- IMRT

The study will be stratified by clinical site and pre-treatment risk factors (e.g., % positive biopsy cores, Gleason score.

* Gleason score 5/6 AND PSA \<10 ng/mL; AND \>=50% positive biopsy cores
* (Gleason score 5/6 and PSA 10-20 ng/mL) OR (Gleason score 7 and PSA 0 - 20 ng/mL); AND \<50% positive biopsy cores
* Gleason score 5/6 and PSA 10-20 ng/mL) OR (Gleason score 7 and PSA 0-20 ng/mL) AND \>=50% positive biopsy cores.

An interim safety analysis (Interim Analysis 1) will be conducted after the first 21 patients in the investigational therapy arm, and a total of 42 subjects in both arms, have completed the 90 day toxicity assessment following randomization (phase 2 component). If, at this point, there are no safety concerns as determined by the Data and Safety Monitoring Board (DSMB), the trial will continue as a phase 3 study with two additional interim analyses (Interim Analyses 2 \& 3). The primary analysis for treatment efficacy will be based on all randomized subjects.

Primary

To assess the relative efficacy of replication-competent adenovirus-mediated suicide gene therapy in combination with 80 Gy intensity modulated radiotherapy (IMRT) versus 80 Gy IMRT alone in patients with newly-diagnosed prostate cancer with an intermediate-risk profile. The primary endpoint is freedom from failure (FFF) (biochemical or clinical).

Secondary

To assess the difference between the two treatment arms for:

* Acute (\<= 90 days) and long-term (\> 90 days) toxicity.
* Prostate biopsy status (12 cores) at 2 years.
* Freedom from distant metastases.
* Disease-specific and overall survival.
* Quality of life.

Exploratory

To examine:

* Possible effect of gene therapy on PSA doubling time (PSADT) after PSA failure.
* Possible association between the primary and secondary outcomes and Ad5-yCD/mutTKSR39rep-ADP adenovirus persistence (as measured by adenoviral DNA in blood).
* Possible association between the primary and secondary outcomes and specific immunological endpoints including levels of circulating CD4+ and CD8+ T lymphocytes, T-cell proliferation response, cytotoxic T lymphocyte (CTL) response, and development of antibodies to prostate-specific antigens.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ad5-yCD/mutTKSR39rep-ADP + IMRT

Gene Therapy + IMRT

Group Type EXPERIMENTAL

Ad5-yCD/mutTKSR39rep-ADP

Intervention Type BIOLOGICAL

Ad5-yCD/mutTKSR39rep-ADP (1 x 10\^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy

IMRT Alone

IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy

Group Type ACTIVE_COMPARATOR

IMRT

Intervention Type RADIATION

40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ad5-yCD/mutTKSR39rep-ADP

Ad5-yCD/mutTKSR39rep-ADP (1 x 10\^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy

Intervention Type BIOLOGICAL

IMRT

40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men with histologically-confirmed adenocarcinoma of the prostate within 180 days prior to registration. To be eligible, the subjects must have one of the following conditions:

* Stage T1 or T2, Gleason Score 7, PSA \<= 20 ng/mL, Any number positive biopsy cores
* Stage T1 or T2, Gleason Score 5 or 6, PSA \>=10 ng/mL and \<20 ng/mL, Any number positive biopsy cores
* Stage T1 or T2, Gleason Score 5 or 6, PSA \<10 ng/mL and \>=50% positive biopsy cores
* Negative lymph nodes as established by imaging, nodal sampling, or dissection within 90 days prior to registration.
* No evidence of metastatic disease as evaluated by bone scan and CT scan of the abdomen and pelvis within 90 days prior to registration
* Karnofsky performance status \>=70
* Subjects must have adequate baseline organ function, as assessed by the following laboratory values, within 30 days before initiating the study
* Adequate renal function with serum creatinine \<=1.5 mg/dL or creatinine clearance \>=45 mL/min/m2.
* Platelet count \> 100,000/μL.
* Absolute neutrophil count \> 1,000/μL.
* Hemoglobin \> 10.0 g/dL.
* Normal partial thromboplastin time (PTT) and prothrombin (PT).
* Bilirubin \< 1.5 mg/dL; SGOT and SGPT \< 2.5 times upper limit of normal (ULN).
* Men of child-producing potential must be willing to consent to use effective contraception while on treatment and for at least 3 months afterwards.
* Subjects must possess the ability to give informed consent and express a willingness to meet all of the expected requirements of the protocol for the duration of the study.

Exclusion Criteria

Subjects with the following conditions will be excluded from the study:

* Stage \>= T3.
* Prostate specific antigen (PSA) \> 20 ng/mL.
* Gleason score \>= 8.
* Prostate volume \>120cc.
* Pathologically positive lymph nodes or nodes \> 1.5 cm on imaging. Note: nodes \> 1.5 cm but biopsy negative are allowed.
* Evidence of M1 metastatic disease.
* Prior invasive malignancy except for non-melanoma skin cancer within 5 years of enrollment.
* Prognosis for survival of \< 5 years.
* Prior radical prostatectomy, cryosurgery for prostate cancer, or bilateral orchiectomy for any reason.
* Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation fields.
* Prior or planned androgen suppression therapy or prior systemic chemotherapy for the study cancer. Note that prior chemotherapy for a different cancer is allowed; however, patients must be \>2 years post-completion of chemotherapy at time of registration. Patients on Proscar therapy must stop to be eligible.
* Severe, active co-morbidity defined as:
* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months.
* Transmural myocardial infarction within the last 6 months.
* Acute infection. Acute infection is defined by any viral, bacterial, or fungal infection that requires specific therapy within 72 hours of initiation of the study therapy.
* Positive serological test for HIV at baseline.
* Previous history of liver disease including hepatitis.
* Immunosuppressive therapy including systemic corticosteroids. Use of inhaled and topical corticosteroids is permitted.
* Impaired immunity or susceptibility to serious viral infections.
* Allergy to any product used in the protocol. (If the subject has an allergy to Ciprofloxacin, another antibiotic can be substituted at the discretion of the treating physician.
* Serious medical or psychiatric illness or concomitant medication, which, in the judgment of the principal investigator, might interfere with the subject's ability to respond to or tolerate the treatment or complete the trial.

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No